Abstract:Immunotherapy has led to a paradigm shift in the treatment of many advanced malignancies. Despite the success in treatment of tumors like non-small cell lung cancer (NSCLC) and melanoma, checkpoint inhibition-based immunotherapy has limitations. Many tumors, such as pancreatic cancer, are less responsive to checkpoint inhibitors, where patients tend to have a limited duration of benefit and where clinical responses are more robust in patients who are positive for predictive biomarkers. One of the critical factors that influence the efficacy of immunotherapy is the tumor microenvironment (TME), which contains a heterogeneous composition of immunosuppressive cells. Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) alter the immune landscape of the TME and serve as facilitators of tumor proliferation, metastatic growth and immunotherapy resistance. Small molecule inhibitors that target these components of the TME have been developed. This special issue review focuses on two promising classes of immunomodulatory small molecule inhibitors: colony stimulating factor-1 receptor (CSF-1R) and focal adhesion kinase (FAK). Small molecule inhibitors of CSF-1R reprogram the TME and TAMs, and lead to enhanced T-cell-mediated tumor eradication. FAK small molecule inhibitors decrease the infiltration MDSCs, TAMs and regulatory T-cells. Additionally, FAK inhibitors are implicated as modulators of stromal density and cancer stem cells, leading to a TME more conducive to an anti-tumor immune response. Immunomodulatory small molecule inhibitors present a unique opportunity to attenuate immune escape of tumors and potentiate the effectiveness of immunotherapy and traditional cytotoxic therapy.

Small-Molecule Targets in Immuno-Oncology

The expanding role for small molecules in immuno-oncology

Small molecule innate immune modulators in cancer therapy

Small Molecule- and Peptide-Based Approaches

Small-molecule agents for cancer immunotherapy

If small molecules immunotherapy comes, can the prime be far behind?

Small molecule inhibitors for cancer immunotherapy and associated biomarkers - the current status

Cancer Immunotherapy: An Overview on Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021).

Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development

Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Tumor Immune Checkpoints and Their Associated Inhibitors

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy

Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics

Development of small molecule drugs targeting immune checkpoints

Posttranslational regulatory mechanism of PD-L1 in cancers and associated opportunities for novel small-molecule therapeutics

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

Small Molecule Inhibitors Targeting the Cancers